Sentences with phrase «number of uncertainties involved»

Given the number of uncertainties involved in trying to estimate a sustainable level of retirement spending — how the markets will perform, how long you'll live, what your actual expenses will be (although on that score, doing a retirement budget can help)-- you might also consider turning a portion of your nest egg into income assured to last no matter how long you live and regardless of how the markets fare by investing in an immediate annuity or longevity annuity.

«Although there are an enormous number of uncertainties involved, the hypothesis is very interesting and worth exploring more.»

Not exact matches

Certain matters discussed in this news release are forward - looking statements that involve a number of risks and uncertainties including, but not limited to, doubts about the Company's ability to continue as a going concern, the need to obtain additional funding, risks in product development plans and schedules, rapid technological change, changes and delays in product approval and introduction, customer acceptance of new products, the impact of competitive products and pricing, market acceptance, the lengthy sales cycle, proprietary rights of the Company and its competitors, risk of operations in Israel, government regulations, dependence on third parties to manufacture products, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission.

The forward - looking statements speak only as of the date made, are based on current assumptions and expectations, and involve a number of risks and uncertainties.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

These statements may involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, including the performance of financial markets, the investment performance of NexPoint Advisors, L.P.'s or Highland Capital Management L.P.'s sponsored investment products, general economic conditions, future acquisitions, competitive conditions and government regulations, including changes in tax laws.

Certain statements in this press release regarding the Company's expected future shipment volumes, gross margins, business prospects and future quarterly or annual results, particularly the management quotations and the statements in the «Business Outlook» section, are forward - looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially.

Certain statements in this press release regarding the Company's expected future shipment volumes, gross margins, and its ability to receive the required government approvals for the sale of six solar power projects in California, are forward - looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially.

Certain statements in this press release regarding the Company's expected future shipment volumes, gross margins, business prospects and future results, are forward - looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially.

Certain statements in this press release are forward - looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially.

Such statements involve a number of risks and uncertainties.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward - looking statements, including, but not limited to: uncertainties involving interpretation of drilling results, environmental matters, lack of ability to obtain required permitting, equipment breakdown or disruptions, and the other factors described in Paramount's disclosures as filed with the SEC.

Forward - looking statements describe RiceBran Technologies» future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of RiceBran Technologies.

With the socioeconomical fallout from Brexit still causing uncertainty, plus announcements entailing a complete overhaul of how the industry is regulated and a number of food safety scandals involving big players like 2 Sisters Food Group — 2017 so far has been tumultuous to say the least.

Forward - looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated.

Cautionary Note Regarding Forward - Looking Statements: Information in this press release that involves Going Loud Studios» expectations, plans or intentions regarding the future are forward - looking statements that are not facts and involve a number of risks and uncertainties.

Cautionary Note Regarding Forward - looking Statements: Information in this press release that involves Activision Publishing's expectations, plans, intentions or strategies regarding the future, including statements about the expected release date, pre-orders, features, functionality and gameplay of Call of Duty: Black Ops 4, are forward - looking statements that are not facts and involve a number of risks and uncertainties.

Cautionary Note Regarding Forward - looking Statements: Information in this press release that involves Activision Publishing's expectations, plans, intentions or strategies regarding the future, including expected release dates, or of the features and functionality of the Call of Duty: Infinite Warfare Season Pass and DLC Map Packs are forward - looking statements that are not facts and involve a number of risks and uncertainties.

Cautionary Note Regarding Forward - looking Statements: Information in this press release that involves Activision Publishing's expectations, plans, intentions or strategies regarding the future, including statements about the expected Call of Duty: Ghosts release date of November 5, 2013, are forward - looking statements that are not facts and involve a number of risks and uncertainties.

Cautionary Note Regarding Forward - looking Statements: Information in this press release that involves Activision Publishing's expectations, plans, intentions or strategies regarding the future are forward - looking statements that are not facts and involve a number of risks and uncertainties.